Most M/M patients clear the virus on their own, resulting in lower success rates when measuring placebo vs. LL on day 14, but because most did improve by Day 3, this improves their chances of stopping the virus from getting worse and leading to hospital stays. Keeping people out of the hospital provides a huge benefit to alleviating overcrowding and overworked medical staffs and could be critical with the flu season closing in. The difference in improvement should be starker in S/C patients who have a much lower rate of improvement on placebo at that advanced stage of infection. Considering its consistent ability to quell the cytokine storm and allow for the less compromised immune systems to clear the virus in ALL treatments on their own thus far, it would be surprising if there were no improvements in this group.